Pedro Rodríguez-Linares

ORCID: 0000-0002-3319-2577
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Autoimmune and Inflammatory Disorders Research
  • Lymphoma Diagnosis and Treatment
  • Drug-Induced Ocular Toxicity
  • Ultrasound in Clinical Applications
  • Peripheral Neuropathies and Disorders
  • Ultrasound and Hyperthermia Applications
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Chronic Lymphocytic Leukemia Research
  • Atherosclerosis and Cardiovascular Diseases
  • Diabetes and associated disorders

Center for Rheumatology
2023

Purpose: To determine the value of lung ultrasound (LUS) compared to high-resolution computed tomography (HRCT) in early diagnosis interstitial disease (ILD) patients with rheumatoid arthritis (RA). Patients and Methods: An observational prospective study was performed. Were included respiratory symptoms or/and, crackles auscultation during medical consultation. All underwent chest X-rays, LUS, HRCT,and function tests. Results: A total 192 RA were included. Mean duration 16.8 ± 11.1 years....

10.2147/oarrr.s441720 article EN cc-by-nc Open Access Rheumatology Research and Reviews 2024-01-01

To assess the frequency of polyautoimmunity (PolyA) in a cohort Colombian patients with systemic lupus erythematosus (SLE) and to identify associated factors.This is an analytical cross-sectional study specialized center., comprehensive review medical records SLE was performed from 2015 2020 order obtain demographic, clinical data, laboratory, treatment information. Associations between PolyA, characteristics disease were explored.A total 463 included analysis. The average age 47.3 ± 15...

10.1016/j.jtauto.2022.100187 article EN cc-by-nc-nd Journal of Translational Autoimmunity 2023-01-01

To describe clinical characteristics and effectiveness of health care in patients with rheumatoid arthritis (RA) as part a multidisciplinary model (MCM) specialized rheumatology center, compared the results national registry RA (NARRA) evidence real-world management.We conducted study (July 1, 2018 to June 30, 2019) based on an analysis electronic records cohort managed "Treat-to-Target" strategy center Colombia MCM, NARRA that includes different models usual care.We have analyzed 7053...

10.2147/oarrr.s385423 article EN cc-by-nc Open Access Rheumatology Research and Reviews 2022-11-01

Background Rheumatoid arthritis (RA) is a chronic disease that affects different areas of the patient's body. Patient education and health literacy essential for them to participate actively in follow-up. Objectives The aim this study was assess differences between clinimetric measurements done by medical team patient-reported outcome measures (PROMs) RA understand impact patient strategies order identify assessment methods. Methods This longitudinal cohort study. It included adult patients...

10.1097/rhu.0000000000002105 article EN cc-by-nc-nd JCR Journal of Clinical Rheumatology 2024-05-29

To describe the effectiveness and persistence of treatment with three anti-TNFα drugs, Infliximab, Etanercept, Adalimumab, in patients Rheumatoid Arthritis (RA) a rheumatology center.

10.2147/btt.s474733 article EN cc-by-nc Biologics 2024-11-01

Purpose: To assess, in a cohort of patients with rheumatoid arthritis (RA) treated subcutaneous antitumor necrosis factor drugs (anti-TNFs), the levels treatment adherence before and after implementing comprehensive care model (CCM). Patients Methods: An observational study including RA under anti-TNFs (adalimumab, etanercept, golimumab) selected at convenience was performed; sample size 125 calculated. The outcome variable assessed Compliance Questionnaire on Rheumatology (CQR19), measured...

10.2147/btt.s385422 article EN cc-by-nc Biologics 2022-11-01

Introduction: The antimalarials chloroquine and hydroxychloroquine have been used for several decades in treating malaria some autoimmune diseases—mainly rheumatoid arthritis (RA) systemic lupus erythematosus (SLE)—with excellent efficacy safety. Due to the massive use of worldwide managing SARS-CoV-2/COVID-19 infection during last 2 years consequent increase cardiac arrhythmia, fear has risen about safety using antimalarials, especially patients with increased cardiovascular risk....

10.3389/fdsfr.2022.1044696 article EN cc-by Frontiers in Drug Safety and Regulation 2023-01-09
Coming Soon ...